These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36401591)

  • 1. Clinical management of psychostimulant withdrawal: review of the evidence.
    Li MJ; Shoptaw SJ
    Addiction; 2023 Apr; 118(4):750-762. PubMed ID: 36401591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Matsuda Y; Iwata N; Correll CU
    J Clin Psychiatry; 2013 Dec; 74(12):e1169-80. PubMed ID: 24434105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of psychostimulant drugs for cocaine dependence.
    Castells X; Casas M; Pérez-Mañá C; Roncero C; Vidal X; Capellà D
    Cochrane Database Syst Rev; 2010 Feb; (2):CD007380. PubMed ID: 20166094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes.
    Lee N; Pennay A; Hester R; McKetin R; Nielsen S; Ferris J
    Drug Alcohol Rev; 2013 Jan; 32(1):88-95. PubMed ID: 22630616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.
    Siefried KJ; Acheson LS; Lintzeris N; Ezard N
    CNS Drugs; 2020 Apr; 34(4):337-365. PubMed ID: 32185696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
    Ahmadi J; Sahraian A; Biuseh M
    Trials; 2019 Jul; 20(1):468. PubMed ID: 31362784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment for amphetamine withdrawal.
    Shoptaw SJ; Kao U; Heinzerling K; Ling W
    Cochrane Database Syst Rev; 2009 Apr; 2009(2):CD003021. PubMed ID: 19370579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal symptoms in abstinent methamphetamine-dependent subjects.
    Zorick T; Nestor L; Miotto K; Sugar C; Hellemann G; Scanlon G; Rawson R; London ED
    Addiction; 2010 Oct; 105(10):1809-18. PubMed ID: 20840201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis.
    Bhatt M; Zielinski L; Baker-Beal L; Bhatnagar N; Mouravska N; Laplante P; Worster A; Thabane L; Samaan Z
    Syst Rev; 2016 Nov; 5(1):189. PubMed ID: 27842569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.
    Tardelli VS; Bisaga A; Arcadepani FB; Gerra G; Levin FR; Fidalgo TM
    Psychopharmacology (Berl); 2020 Aug; 237(8):2233-2255. PubMed ID: 32601988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal.
    Acheson LS; Ezard N; Lintzeris N; Dunlop A; Brett J; Rodgers C; Gill A; Christmass M; McKetin R; Farrell M; Shoptaw S; Siefried KJ
    PLoS One; 2022; 17(10):e0275371. PubMed ID: 36190973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nature, time course and severity of methamphetamine withdrawal.
    McGregor C; Srisurapanont M; Jittiwutikarn J; Laobhripatr S; Wongtan T; White JM
    Addiction; 2005 Sep; 100(9):1320-9. PubMed ID: 16128721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders.
    Amin-Esmaeili M; Susukida R; Johnson RM; Farokhnia M; Crum RM; Thrul J; Mojtabai R
    Drug Alcohol Depend; 2021 Sep; 226():108904. PubMed ID: 34304121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of psychostimulant drugs for amphetamine abuse or dependence.
    Pérez-Mañá C; Castells X; Torrens M; Capellà D; Farre M
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009695. PubMed ID: 23996457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms.
    Calpe-López C; García-Pardo MP; Aguilar MA
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31315244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
    Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
    Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatments for methamphetamine abuse: a literature review for the clinician.
    Brackins T; Brahm NC; Kissack JC
    J Pharm Pract; 2011 Dec; 24(6):541-50. PubMed ID: 22095579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of stimulants to treat cocaine and methamphetamine abuse.
    Moeller FG; Schmitz JM; Herin D; Kjome KL
    Curr Psychiatry Rep; 2008 Oct; 10(5):385-91. PubMed ID: 18803911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial.
    Thompson RG; Oliveto A; Thostenson JD; Wilson MP; McGaugh J; Mancino MJ
    J Psychopharmacol; 2021 Nov; 35(11):1420-1430. PubMed ID: 34697965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.
    Neisewander JL; Cheung TH; Pentkowski NS
    Neuropharmacology; 2014 Jan; 76 Pt B(0 0):301-19. PubMed ID: 23973315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.